Stay updated on Azacitidine and Quizartinib in FLT3/CBL-Mutated MDS/MPN Clinical Trial
Sign up to get notified when there's something new on the Azacitidine and Quizartinib in FLT3/CBL-Mutated MDS/MPN Clinical Trial page.

Latest updates to the Azacitidine and Quizartinib in FLT3/CBL-Mutated MDS/MPN Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedA new revision (v3.4.2) was added to the record history, and an earlier revision (v3.4.1) was removed, along with a government funding notice. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.7%

- Check20 days agoChange DetectedA government funding notice was added and the page revision was updated to v3.4.1, replacing v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.7%

- Check28 days agoChange DetectedUI updates include Show glossary, color-coded change indicators (green/red highlights), and revised revision notes; core study data and functionality remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

- Check42 days agoChange DetectedA new revision entry 'Revision: v3.3.4' was added to the record history, replacing the earlier 'Revision: v3.3.3'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedRevision: v3.3.3 is now displayed and the HHS Vulnerability Disclosure footer link was removed; these are cosmetic changes that do not affect study data or core functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check92 days agoChange DetectedNew revision entry v3.3.2 added. Revision v3.2.0 removed.SummaryDifference0.1%

Stay in the know with updates to Azacitidine and Quizartinib in FLT3/CBL-Mutated MDS/MPN Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Azacitidine and Quizartinib in FLT3/CBL-Mutated MDS/MPN Clinical Trial page.